[144] Rocket Pharmaceuticals, Inc. SEC Filing
Form 144 filed for Rocket Pharmaceuticals, Inc. (RCKT) reports a proposed sale of 1,680 common shares through Fidelity Brokerage Services on 08/18/2025 with an aggregate market value of $5,149.54. The filing shows these shares were acquired on 08/14/2025 via restricted stock vesting and paid as compensation. The issuer's outstanding share count is listed as 107,903,871. The filer previously sold 801 shares on 05/20/2025 for $5,163.25 and 11,161 shares on 08/14/2025 for $33,691.71. The notice includes the standard representation that the seller is not aware of undisclosed material adverse information.
Modello 144 depositato per Rocket Pharmaceuticals, Inc. (RCKT) segnala una proposta di vendita di 1.680 azioni ordinarie tramite Fidelity Brokerage Services in data 18/08/2025 per un valore di mercato complessivo di $5.149,54. La dichiarazione indica che queste azioni sono state ottenute il 14/08/2025 mediante vesting di azioni soggette a restrizioni e corrisposte come compenso. Il numero totale di azioni in circolazione dell'emittente 猫 indicato come 107.903.871. Il dichiarante aveva precedentemente venduto 801 azioni il 20/05/2025 per $5.163,25 e 11.161 azioni il 14/08/2025 per $33.691,71. L'avviso include la consueta dichiarazione che il venditore non 猫 a conoscenza di informazioni materiali sfavorevoli non divulgate.
Formulario 144 presentado para Rocket Pharmaceuticals, Inc. (RCKT) informa una propuesta de venta de 1.680 acciones ordinarias a trav茅s de Fidelity Brokerage Services el 18/08/2025 por un valor de mercado agregado de $5.149,54. El informe indica que estas acciones se adquirieron el 14/08/2025 mediante vesting de acciones restringidas y fueron pagadas como 肠辞尘辫别苍蝉补肠颈贸苍. El n煤mero de acciones en circulaci贸n del emisor figura como 107.903.871. El declarante vendi贸 anteriormente 801 acciones el 20/05/2025 por $5.163,25 y 11.161 acciones el 14/08/2025 por $33.691,71. El aviso incluye la representaci贸n est谩ndar de que el vendedor no conoce informaci贸n adversa material no divulgada.
Rocket Pharmaceuticals, Inc. (RCKT)鞐� 雽�頃� Form 144 鞝滌稖鞚赌 2025-08-18鞐� Fidelity Brokerage Services毳� 韱淀暣 1,680 氤错喌欤茧ゼ 毵る弰頃� 鞓堨爼鞚措┌ 齑� 鞁滉皜臧� $5,149.54霛缄碃 氤搓碃頃╇媹雼�. 靹滊鞐� 霐半ゴ氅� 頃措嫻 欤检嫕鞚赌 2025-08-14鞐� 鞝滍暅欤� 氤挫湢 旮瓣皠(vested restricted stock)鞐� 霐半澕 旆摑霅橃棃瓿� 氤挫垬搿� 歆�旮夒悩鞐堨姷雼堧嫟. 氚滍枆須岇偓鞚� 氚滍枆 欤检嫕 靾橂姅 107,903,871搿� 旮办灛霅橃柎 鞛堨姷雼堧嫟. 鞝滌稖鞛愲姅 鞚挫爠鞐� 2025-05-20鞐� 801欤茧ゼ $5,163.25鞐�, 2025-08-14鞐� 11,161欤茧ゼ $33,691.71鞐� 毵り皝頃� 氚� 鞛堨姷雼堧嫟. 韱奠靹滌棎電� 韺愲Г鞛愱皜 瓿店皽霅橃 鞎婌澏� 欷戨寑頃� 攵堧Μ頃� 鞝曤炒臧� 鞐嗢潓鞚� 鞎岅碃 鞛堧嫟電� 響滌 歆勳垹鞚� 韽暔霅橃柎 鞛堨姷雼堧嫟.
Formulaire 144 d茅pos茅 pour Rocket Pharmaceuticals, Inc. (RCKT) signale une proposition de vente de 1 680 actions ordinaires via Fidelity Brokerage Services le 18/08/2025 pour une valeur marchande totale de 5 149,54 $. Le dossier indique que ces actions ont 茅t茅 acquises le 14/08/2025 par vesting d'actions restreintes et vers茅es en tant que 谤茅尘耻苍茅谤补迟颈辞苍. Le nombre d'actions en circulation de l'茅metteur est indiqu茅 脿 107 903 871. Le d茅clarant a pr茅c茅demment vendu 801 actions le 20/05/2025 pour 5 163,25 $ et 11 161 actions le 14/08/2025 pour 33 691,71 $. L'avis comprend la d茅claration standard selon laquelle le vendeur n'est pas au courant d'informations d茅favorables importantes non divulgu茅es.
Formular 144 eingereicht 蹿眉谤 Rocket Pharmaceuticals, Inc. (RCKT) meldet einen geplanten Verkauf von 1.680 Stammaktien 眉ber Fidelity Brokerage Services am 18.08.2025 mit einem aggregierten Marktwert von $5.149,54. Die Einreichung zeigt, dass diese Aktien am 14.08.2025 durch Vesting eingeschr盲nkter Aktien erworben und als 痴别谤驳眉迟耻苍驳 ausgezahlt wurden. Die ausstehenden Aktien des Emittenten werden mit 107.903.871 angegeben. Der Meldende hat zuvor 801 Aktien am 20.05.2025 蹿眉谤 $5.163,25 und 11.161 Aktien am 14.08.2025 蹿眉谤 $33.691,71 verkauft. Die Mitteilung enth盲lt die 眉bliche Zusicherung, dass dem Verk盲ufer keine nicht offengelegten, wesentlichen nachteiligen Informationen bekannt sind.
- Timely disclosure of proposed insider sale under Rule 144 demonstrating regulatory compliance
- Securities acquired via restricted stock vesting and paid as compensation, indicating standard equity compensation monetization
- Prior sales disclosed for transparency (801 shares on 05/20/2025 and 11,161 shares on 08/14/2025)
- None.
Insights
TL;DR: Routine insider disclosure showing small sales following restricted stock vesting; no material change to capitalization.
The Form 144 documents a proposed sale of 1,680 shares valued at $5,149.54, acquired by restricted stock vesting on 08/14/2025. Given the issuer's reported 107,903,871 shares outstanding, the amount scheduled for sale represents a de minimis fraction of total equity and is unlikely to be material to valuation or liquidity. Prior reported sales of 801 and 11,161 shares in the past three months are disclosed, supporting transparency around insider trading activity. This filing fulfills Rule 144 disclosure obligations without indicating company-level operational or financial developments.
TL;DR: The filing reflects compliance with disclosure rules after compensation-related vesting; no governance red flags apparent.
The seller reports acquisition via restricted stock vesting and timely notice of proposed sales through a broker, which aligns with standard governance practices for equity compensation monetization. The document includes the required declaration that the seller is unaware of undisclosed material adverse information. There are no disclosures here of unusual trading plans, accelerated sales, or insider departures. From a governance perspective, this is a routine, compliant insider transaction filing.
Modello 144 depositato per Rocket Pharmaceuticals, Inc. (RCKT) segnala una proposta di vendita di 1.680 azioni ordinarie tramite Fidelity Brokerage Services in data 18/08/2025 per un valore di mercato complessivo di $5.149,54. La dichiarazione indica che queste azioni sono state ottenute il 14/08/2025 mediante vesting di azioni soggette a restrizioni e corrisposte come compenso. Il numero totale di azioni in circolazione dell'emittente 猫 indicato come 107.903.871. Il dichiarante aveva precedentemente venduto 801 azioni il 20/05/2025 per $5.163,25 e 11.161 azioni il 14/08/2025 per $33.691,71. L'avviso include la consueta dichiarazione che il venditore non 猫 a conoscenza di informazioni materiali sfavorevoli non divulgate.
Formulario 144 presentado para Rocket Pharmaceuticals, Inc. (RCKT) informa una propuesta de venta de 1.680 acciones ordinarias a trav茅s de Fidelity Brokerage Services el 18/08/2025 por un valor de mercado agregado de $5.149,54. El informe indica que estas acciones se adquirieron el 14/08/2025 mediante vesting de acciones restringidas y fueron pagadas como 肠辞尘辫别苍蝉补肠颈贸苍. El n煤mero de acciones en circulaci贸n del emisor figura como 107.903.871. El declarante vendi贸 anteriormente 801 acciones el 20/05/2025 por $5.163,25 y 11.161 acciones el 14/08/2025 por $33.691,71. El aviso incluye la representaci贸n est谩ndar de que el vendedor no conoce informaci贸n adversa material no divulgada.
Rocket Pharmaceuticals, Inc. (RCKT)鞐� 雽�頃� Form 144 鞝滌稖鞚赌 2025-08-18鞐� Fidelity Brokerage Services毳� 韱淀暣 1,680 氤错喌欤茧ゼ 毵る弰頃� 鞓堨爼鞚措┌ 齑� 鞁滉皜臧� $5,149.54霛缄碃 氤搓碃頃╇媹雼�. 靹滊鞐� 霐半ゴ氅� 頃措嫻 欤检嫕鞚赌 2025-08-14鞐� 鞝滍暅欤� 氤挫湢 旮瓣皠(vested restricted stock)鞐� 霐半澕 旆摑霅橃棃瓿� 氤挫垬搿� 歆�旮夒悩鞐堨姷雼堧嫟. 氚滍枆須岇偓鞚� 氚滍枆 欤检嫕 靾橂姅 107,903,871搿� 旮办灛霅橃柎 鞛堨姷雼堧嫟. 鞝滌稖鞛愲姅 鞚挫爠鞐� 2025-05-20鞐� 801欤茧ゼ $5,163.25鞐�, 2025-08-14鞐� 11,161欤茧ゼ $33,691.71鞐� 毵り皝頃� 氚� 鞛堨姷雼堧嫟. 韱奠靹滌棎電� 韺愲Г鞛愱皜 瓿店皽霅橃 鞎婌澏� 欷戨寑頃� 攵堧Μ頃� 鞝曤炒臧� 鞐嗢潓鞚� 鞎岅碃 鞛堧嫟電� 響滌 歆勳垹鞚� 韽暔霅橃柎 鞛堨姷雼堧嫟.
Formulaire 144 d茅pos茅 pour Rocket Pharmaceuticals, Inc. (RCKT) signale une proposition de vente de 1 680 actions ordinaires via Fidelity Brokerage Services le 18/08/2025 pour une valeur marchande totale de 5 149,54 $. Le dossier indique que ces actions ont 茅t茅 acquises le 14/08/2025 par vesting d'actions restreintes et vers茅es en tant que 谤茅尘耻苍茅谤补迟颈辞苍. Le nombre d'actions en circulation de l'茅metteur est indiqu茅 脿 107 903 871. Le d茅clarant a pr茅c茅demment vendu 801 actions le 20/05/2025 pour 5 163,25 $ et 11 161 actions le 14/08/2025 pour 33 691,71 $. L'avis comprend la d茅claration standard selon laquelle le vendeur n'est pas au courant d'informations d茅favorables importantes non divulgu茅es.
Formular 144 eingereicht 蹿眉谤 Rocket Pharmaceuticals, Inc. (RCKT) meldet einen geplanten Verkauf von 1.680 Stammaktien 眉ber Fidelity Brokerage Services am 18.08.2025 mit einem aggregierten Marktwert von $5.149,54. Die Einreichung zeigt, dass diese Aktien am 14.08.2025 durch Vesting eingeschr盲nkter Aktien erworben und als 痴别谤驳眉迟耻苍驳 ausgezahlt wurden. Die ausstehenden Aktien des Emittenten werden mit 107.903.871 angegeben. Der Meldende hat zuvor 801 Aktien am 20.05.2025 蹿眉谤 $5.163,25 und 11.161 Aktien am 14.08.2025 蹿眉谤 $33.691,71 verkauft. Die Mitteilung enth盲lt die 眉bliche Zusicherung, dass dem Verk盲ufer keine nicht offengelegten, wesentlichen nachteiligen Informationen bekannt sind.
FAQ
What does Rocket Pharmaceuticals (RCKT) Form 144 disclose?
How were the RCKT shares acquired that are being sold?
Has the filer sold RCKT shares recently?
What is the issuer's outstanding share count reported in the filing?
Through which broker will the proposed sale be executed?
